Leuprolide and cetrorelix both ultimately suppress reproductive hormones, but through opposite pharmacology — a classic teaching example. Leuprolide is a GnRH agonist: continuous use overstimulates and then desensitizes the receptor, causing an initial hormone "flare" before suppression. Cetrorelix is a GnRH antagonist: it blocks the receptor directly, suppressing hormones immediately with no flare. Both are FDA-approved.
At a glance
| Leuprolide | Cetrorelix | |
|---|---|---|
| Class | GnRH agonist | GnRH antagonist |
| Brand name | Lupron | Cetrotide |
| FDA status | Approved | Approved |
| Onset of suppression | After an initial hormone 'flare' | Immediate, no flare |
| Typical uses | Prostate cancer, endometriosis, precocious puberty, IVF | Preventing premature ovulation in IVF |
| Mechanism | Overstimulate then desensitize receptor | Block receptor directly |
The bottom line
Bottom line: Both lower sex hormones, but the route matters clinically. Leuprolide (an agonist) causes a temporary flare before suppression, which is why it's used where sustained suppression is the goal. Cetrorelix (an antagonist) suppresses immediately without a flare, which is why it's favored in IVF to prevent premature ovulation. Both are approved prescription medicines.
Frequently asked questions
What's the difference between leuprolide and cetrorelix?
Leuprolide is a GnRH agonist that suppresses hormones after an initial flare, while cetrorelix is a GnRH antagonist that blocks the receptor and suppresses hormones immediately with no flare. Both are FDA-approved.
Why does leuprolide cause a 'flare'?
As a GnRH agonist, leuprolide first overstimulates the receptor (briefly raising hormones) before desensitizing it and suppressing hormone production. Antagonists like cetrorelix skip this flare.
Which is used in IVF?
Both can be used in fertility treatment, but cetrorelix (an antagonist) is specifically used to prevent premature ovulation because it suppresses immediately without a flare. Leuprolide has broader uses including prostate cancer and endometriosis.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Wojciechowski NJ, Carter CA, Skoutakis VA, et al. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. Drug Intell Clin Pharm. 1986. Peer-reviewed study
- Ko YH, Ha YR, Kim JW, et al. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist leuprolide on androgen-independent prostate cancer (DU145). J Int Med Res. 2011. Peer-reviewed study
- Wilson AC, Meethal SV, Bowen RL, et al. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007. Peer-reviewed study
- Teutonico D, Montanari S, Ponchel G. Leuprolide acetate: pharmaceutical use and delivery potentials. Expert Opin Drug Deliv. 2012. Peer-reviewed study
- Van Gerpen JA, McKinley KL. Leuprolide-induced myopathy. J Am Geriatr Soc. 2002. Peer-reviewed study
- Cox MC, Scripture CD, Figg WD. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?. Expert Rev Anticancer Ther. 2005. Peer-reviewed study
- Lee TH, Lin YH, Seow KM, et al. Effectiveness of cetrorelix for prevention of premature LH surge during controlled ovarian stimulation: a randomized trial. Fertil Steril. 2008. Peer-reviewed study
- Lin YH, Seow KM, Chen HJ, et al. Effect of cetrorelix dose on premature LH surge during ovarian stimulation. Reprod Biomed Online. 2008. Peer-reviewed study
- Finas D, Hornung D, Diedrich K, et al. Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother. 2006. Peer-reviewed study
- Tur-Kaspa I, Ezcurra D. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology. Expert Opin Drug Metab Toxicol. 2009. Peer-reviewed study
- Reissmann T, Schally AV, Bouchard P, et al. The LHRH antagonist cetrorelix: a review. Hum Reprod Update. 2000. Peer-reviewed study
- Kanda A, Nobukiyo A, Sotomaru Y. Effect of Cetrorelix administration on ovarian stimulation in aged mice. Exp Anim. 2021. Peer-reviewed study